| Followers | 59 |
| Posts | 7589 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Saturday, December 12, 2020 6:22:18 AM
Exactly! With a worldwide pandemic, one that may eventually impact every
human on the planet, AMRN has a medication that may be key to providing
a remedy to the residual health impact (for many) from having had this
virus. Early on it was determined that the virus resulted in inflammation
of the Endothelium...This is EXACTLY the area that Vascepa has been shown
to reduce the inflammation of and help to heal! WHY CAN'T AMRN GET
TRACTION ON THIS? Simple answer: They can't even gain traction for
having a medication that helps remedy the biggest killer on the planet,
CVD.
So is the problem management? Is it a vast conspiracy of BP to keep
Vascepa from gaining a foothold? Is it the seeming inability of the FDA
to do their job in a way that benefits and protects the health of the
citizens which they are there to serve? Is it the "political agenda"
that only benefits those that "they" choose to benefit? Is it all of
above? (Hint...Who is Steve Nissen and why is he so strangely negative?)
The solution is obvious. For the sake of those who would benefit from
this amazing medication let us hope that the AMRN board of directors
come to the same conclusion that I have a long time ago.
human on the planet, AMRN has a medication that may be key to providing
a remedy to the residual health impact (for many) from having had this
virus. Early on it was determined that the virus resulted in inflammation
of the Endothelium...This is EXACTLY the area that Vascepa has been shown
to reduce the inflammation of and help to heal! WHY CAN'T AMRN GET
TRACTION ON THIS? Simple answer: They can't even gain traction for
having a medication that helps remedy the biggest killer on the planet,
CVD.
So is the problem management? Is it a vast conspiracy of BP to keep
Vascepa from gaining a foothold? Is it the seeming inability of the FDA
to do their job in a way that benefits and protects the health of the
citizens which they are there to serve? Is it the "political agenda"
that only benefits those that "they" choose to benefit? Is it all of
above? (Hint...Who is Steve Nissen and why is he so strangely negative?)
The solution is obvious. For the sake of those who would benefit from
this amazing medication let us hope that the AMRN board of directors
come to the same conclusion that I have a long time ago.
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
